Verbatim response from ChatGPT
Short answer: probably not reliably. Compounded “GLP‑1 drops” or tablets made by mixing up injectable drugs are unproven, inconsistent, and risky. Use FDA‑approved products or a prescriber‑supervised plan instead.
Why compounded oral GLP‑1s are unreliable
- Peptides are fragile: GLP‑1 drugs (semaglutide, tirzepatide) are peptides that are normally destroyed by stomach acid and digestive enzymes. An approved oral product (Rybelsus, oral semaglutide from Novo Nordisk) uses a specific absorption enhancer (SNAC) and a carefully controlled formulation and dosing schedule to get meaningful absorption. Compounded drops/tablets generally do not include or validate that technology.
- No good evidence: There are no high‑quality clinical trials showing that pharmacy‑compounded oral GLP‑1 drops/tablets provide reliable blood levels, glucose control, or weight loss comparable to the approved drugs.
- Big variability and safety risks: Compounded products can have inconsistent doses, degraded drug, contamination, or stability/cold‑chain problems. They are not reviewed or approved by the FDA for safety, potency, or purity in the way commercial drugs are.
- Regulatory/legality and counterfeit risk: Some online sellers of “GLP‑1 drops” are effectively selling unapproved or repackaged products. That raises legal and safety concerns.
What is proven to work
- Injectable GLP‑1 receptor agonists and related drugs (examples: semaglutide as Ozempic for diabetes and Wegovy for weight loss; tirzepatide as Mounjaro for diabetes and Zepbound for weight loss; dulaglutide as Trulicity) have robust clinical trial evidence for blood‑sugar lowering and weight loss.
- The only approved oral GLP‑1 is Rybelsus (oral semaglutide) — it’s specifically formulated and tested; it requires special instructions (take fasting with a small sip of water and wait before eating) to work.
Practical advice
- Don’t rely on compounded drops/tablets sold online or through unverified pharmacies. They may not give you the dose you expect and could be unsafe.
- If you want an oral option, ask your clinician whether Rybelsus (oral semaglutide) is appropriate and safe for you.
- If injectables are acceptable, discuss proven medicines (Ozempic, Wegovy, Mounjaro, Trulicity) with your clinician — they have predictable effects and safety data.
- If cost or access is the issue, ask your prescriber about manufacturer patient‑assistance programs, coupons, or clinical trials—many companies offer help programs.
- If you already have a compounded product, stop it and consult your clinician. Get monitoring (blood glucose, kidney function if indicated) and report any adverse effects.
If you want, tell me whether you’re considering these for diabetes or weight loss and whether you have a prescriber — I can suggest safer options and how to discuss them with your clinician.